Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bexmarilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bexmarilimab overview

Bexmarilimab is under development for the treatment of hematological tumors including myelodysplastic syndrome, chronic myelomonocytic leukemia, relapsed and refractory acute myeloid leukemia, advanced or metastatic hepatocellular carcinoma, hepatobiliary system tumor, gallbladder cancer, bladder cancer, intrahepatic or extrahepatic cholangiocarcinoma, colorectal cancer, anaplastic thyroid cancer, ovarian cancer, pancreatic ductal adenocarcinoma, metastatic uveal melanoma, gastric cancer including adenocarcinoma of the gastroesophageal junction, head and neck cancer squamous cell carcinoma, transitional cell cancer (urothelial cell cancer), metastatic breast cancer, cutaneous melanoma, head and neck cancer squamous cell carcinoma and urothelial cancer. The drug candidate is a humanized monoclonal IgG4 antibody targeting cells expressing CLEVER-1 (Common lymphatic endothelial and vascular endothelial receptor-1). It is administered intravenous and formulation in the form of solution. The drug candidate is based on the composite human antibody technology. The drug candidate is devoid of T cell epitopes which limits mounting of immune reaction against FP-1304.

It was under development for the treatment of renal cell cancer, colon cancer, TAM positive Hodgkin lymphoma, anti-CD20 resistant, lymphoma, tuberculosis, pertussis, glioblastoma, hematological tumor and opportunistic infections.

Faron Pharmaceuticals overview

Faron Pharmaceuticals (Faron) is a clinical-stage biopharmaceutical company that develops novel treatments for medical conditions. The company’s clinical pipeline comprises of Traumakine, Bexmarilimab and Haematokine. Its Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. The company’s Haematokine is an investigational Vascular Adhesion Protein 1 (VAP-1) inhibitor that blocks VAP-1 enzymatic activity to support the expansion of human hematopoietic stem cells. The company works in collaboration with academic institutions, pharmaceutical companies and contract research organizations for clinical development programs. Faron is headquartered in Turku, Finland.

For a complete picture of Bexmarilimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.